AI Summary & Key Takeaways
AI InsightConclusion: In MM and plasma celll leukemia in which there is potential for rituximab use, it is suggested that combination with zoledronic acid may not be a suitable approach.
📌 3 Key Takeaways
Abstract
Aim: In this study, we have invastigated the anti-myeloma effect of the combination of these two agents againts CD 20 antigen positive and negative multpile myeloma (MM) cell lines. Material and Method: ARH-77 and RPMI-8226 were cultured with rituximab and zoledronic acid singly or combination. After evaluation for proliferation inhibition CD20 measurements is made for ARH-77 cell line and RPMI-8226 cell line in efficient concentrations. Findings: We have found that these two agents had antagonistic activity againts both ARH-77 and RPMI-8226 cell lines. As an unexpected finding, complement alone exhibited prominent proliferative activity on RPMI -8226 cells. Conclusion: In MM and plasma celll leukemia in which there is potential for rituximab use, it is suggested that combination with zoledronic acid may not be a suitable approach.
Özet
Amaç: Bu çalışmada multipl miyelom hücre serilerinde CD 20 antijeni pozitif ve negatif hücre serilerinde rituksimab ve zoledronik asitin anti-miyelom etkilerini araştırdık. Gereç ve Yöntem: ARH-77 (CD20 pozitif) ve RPMI-8226 (CD20 negatif) multipl miyelom hücre serileri rituksimab ve zoledronik asit ile tek veya birlikte kültüre edildi. ARH-77 hücre serileri ve RPMI 8226 hücre serilerinde CD20 baskılayıcı etkileri araştırıldı. Bulgular: Çalışmada bu iki maddenin antagonistik aktivite gösterdiklerini saptadık. Kompleman tek başına RPMI 8226 hücre serilerinde proliferatif etki gösterdi. Sonuç: Multipl miyelom ve plazma hücre lösemilerinde rituksimab kullanımının uygun bir yaklaşım olmadığını düşünüyoruz.